Company Filing History:
Years Active: 2004
Title: Jiangchun Wu: Innovator in Antibody Fragment Technology
Introduction
Jiangchun Wu is a prominent inventor based in Fremont, CA, known for his significant contributions to the field of biotechnology. He has developed innovative methods for creating antibody fragments, which have important applications in medical research and therapeutic development. His work has led to advancements that enhance the efficacy of antibody-based treatments.
Latest Patents
Jiangchun Wu holds a patent titled "Methods for making antibody fragments and compositions resulting therefrom." This patent describes improved methods for producing antibody fragments, particularly F(ab′) fragments, from various classes and subclasses of antibodies. The process involves pretreating antibodies with deglycosylases or inhibiting glycosylation during expression. This approach results in antibodies that are more susceptible to protease cleavage, specifically pepsinolysis, yielding F(ab′) antibody fragments. The patent also discloses compositions resulting from these innovative methods.
Career Highlights
Jiangchun Wu is currently employed at Zyomix, Inc., where he continues to push the boundaries of antibody technology. His work has been instrumental in developing new techniques that improve the production and functionality of antibody fragments. With a focus on enhancing therapeutic applications, Wu's contributions are paving the way for more effective treatments in various medical fields.
Collaborations
Jiangchun Wu collaborates with notable colleagues, including Steffen Nock and David Wilson. Their combined expertise fosters a dynamic research environment that drives innovation in antibody fragment technology.
Conclusion
Jiangchun Wu's work exemplifies the spirit of innovation in biotechnology. His patented methods for producing antibody fragments represent a significant advancement in the field, with the potential to improve therapeutic outcomes. Wu's contributions continue to shape the future of antibody-based treatments, making him a key figure in this area of research.